Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Tablets × Dermatologic × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 5 Other hematologic neoplasm 5 Thoracic 4 Lymphoid 3 Tumor-Agnostic 2 Plasma cell 2 Head & Neck 2 Genitourinary 2 Gastrointestinal 2 Sarcoma 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Skin Neoplasms 1 Melanoma 1

Interventions

pembrolizumab 149 Nivolumab 101 Ipilimumab 85 Dacarbazine 36 trametinib 33 3-ingenyl angelate 32 dabrafenib 29 Vemurafenib 27 cemiplimab 24 atezolizumab 20 Imiquimod 20 Temozolomide 19 binimetinib 16 Paclitaxel 16 cobimetinib 14 Aminolevulinic Acid 14 spartalizumab 13 avelumab 13 Carboplatin 13 Fluorouracil 12 Cyclophosphamide 11 Cisplatin 11 encorafenib 10 HhAntag691 10 Bevacizumab 10 talimogene laherparepvec 9 relatlimab 9 lenvatinib 9 durvalumab 9 Gels 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡